Emergent BioSolutions (EBS) Misses Q2 EPS by 43c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.01 --0%
Revenue Growth %: +32.0%
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +32.0%
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($1.06), $0.43 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $337.9 million versus the consensus estimate of $217.03 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- EXL to acquire iMerit in deal valued at up to $310 million
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
